

# Marwan Kwok

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4303897/publications.pdf>

Version: 2024-02-01

26  
papers

1,141  
citations

933264

10  
h-index

642610

23  
g-index

27  
all docs

27  
docs citations

27  
times ranked

2110  
citing authors

#	ARTICLE	IF	CITATIONS
1	Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2008, 359, 575-583.	13.9	518
2	ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. <i>Blood</i> , 2016, 127, 582-595.	0.6	214
3	Minimal residual disease is an independent predictor for 10-year survival in CLL. <i>Blood</i> , 2016, 128, 2770-2773.	0.6	106
4	Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway. <i>Lancet, The</i> , 2015, 385, S58.	6.3	69
5	USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status. <i>Blood</i> , 2017, 130, 156-166.	0.6	60
6	Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. <i>Leukemia</i> , 2005, 19, 1896-1904.	3.3	52
7	Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia. <i>Frontiers in Immunology</i> , 2019, 10, 2832.	2.2	34
8	Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL. <i>Blood</i> , 2020, 135, 411-428.	0.6	17
9	Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts. <i>Oncotarget</i> , 2017, 8, 44749-44760.	0.8	13
10	Minimal Residual Disease Is a Predictor for Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia (CLL) That Is Independent of the Type or Line of Therapy.. <i>Blood</i> , 2009, 114, 540-540.	0.6	12
11	Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective. <i>Frontiers in Oncology</i> , 2021, 11, 790004.	1.3	11
12	Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. <i>Cancers</i> , 2021, 13, 4681.	1.7	9
13	Cancer and COVID-19: On the Quest for Effective Vaccines. <i>Blood Cancer Discovery</i> , 2021, 2, 13-18.	2.6	5
14	Independent prognostic significance of minimal residual disease status in chronic lymphocytic leukaemia. <i>Lancet, The</i> , 2014, 383, S66.	6.3	4
15	Kinetics of CLL Subclonal Architecture: Spontaneous Disease Progression or Treatment-Induced Selection?. <i>Blood</i> , 2015, 126, 167-167.	0.6	4
16	Targeting the Ataxia Telangiectasia and Rad3 Signaling Pathway to Overcome Chemoresistance in Cancer. , 2019, , 203-230.		2
17	Synthetic Lethality In CLL With DNA Damage Response Defect By Targeting ATR Pathway. <i>Blood</i> , 2013, 122, 120-120.	0.6	2
18	PALB2 variant status in hematological malignancies – a potential therapeutic target?. <i>Leukemia and Lymphoma</i> , 2019, 60, 1823-1826.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Genetics in the era of targeted CLL therapy. Blood, 2020, 135, 2333-2334.	0.6	1
20	Ibrutinib: another string to its bow. Blood, 2021, 137, 3461-3462.	0.6	1
21	Monoclonal B-Cell Lymphocytosis (MBL) Is a Precursor State for Chronic Lymphocytic Leukemia (CLL) with 1% Progression Per Year.. Blood, 2007, 110, 749-749.	0.6	1
22	ATR Inhibition Exacerbates Replication Stress in TP53 or ATM Deficient CLL Cells and Enhances Sensitivity to Chemotherapy and Targeted Therapy. Blood, 2014, 124, 3340-3340.	0.6	1
23	PB1946 OUTCOMES FOLLOWING TREATMENT DISCONTINUATION IN CML: REAL-WORLD EXPERIENCE FROM 3 REGIONAL UK CENTRES. HemaSphere, 2019, 3, 884-885.	1.2	1
24	CLL Progression Is Associated with Increased Clonal Diversity and Replication Stress. Blood, 2014, 124, 1977-1977.	0.6	0
25	The three musketeers: uniting against CLL. Blood, 2022, 139, 1264-1265.	0.6	0
26	Linking epigenome regulation with DNA repair. Blood, 2022, 139, 3356-3357.	0.6	0